Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
XERS Xeris Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: XERS
Price (delayed)
$4.75
Market cap
$760.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$971.05M
Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Highlights
XERS's EPS is up by 35% year-on-year and by 19% since the previous quarter
The company's revenue rose by 30% YoY and by 10% QoQ
XERS's quick ratio is down by 36% year-on-year
XERS's equity is down by 19% since the previous quarter
Key stats
What are the main financial stats of XERS
Market
Valuations
Earnings
Shares outstanding
160.16M
Market cap
$760.74M
Enterprise value
$971.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.36
Revenue
$222.55M
Gross profit
$182.96M
Operating income
-$22.49M
Net income
-$45.08M
EBIT
-$16.89M
EBITDA
-$4.34M
Free cash flow
-$27.43M
Per share
Balance sheet
Liquidity
EPS
-$0.3
EPS diluted
-$0.3
Free cash flow per share
-$0.18
Book value per share
-$0.23
Revenue per share
$1.46
TBVPS
$1.29
Total assets
$315.45M
Total liabilities
$350.58M
Debt
$268.75M
Equity
-$35.13M
Working capital
$68.42M
Debt to equity
-7.65
Current ratio
1.72
Quick ratio
1.1
Net debt/EBITDA
-48.47
Margins
Efficiency
Dividend
EBITDA margin
-1.9%
Gross margin
82.2%
Net margin
-20.3%
Operating margin
-10.1%
Return on assets
-14%
Return on equity
N/A
Return on invested capital
-5.3%
Return on capital employed
-7.7%
Return on sales
-7.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XERS stock price
How has the Xeris Pharmaceuticals stock price performed over time
Intraday
0.42%
1 week
0.21%
1 month
2.15%
1 year
128.37%
YTD
40.12%
QTD
1.71%
Financial performance
How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$222.55M
Gross profit
$182.96M
Operating income
-$22.49M
Net income
-$45.08M
Gross margin
82.2%
Net margin
-20.3%
Xeris Pharmaceuticals's operating margin has soared by 61% YoY and by 39% from the previous quarter
The operating income has grown by 50% year-on-year and by 33% since the previous quarter
The net margin has grown by 46% YoY and by 25% from the previous quarter
The company's revenue rose by 30% YoY and by 10% QoQ
Price vs fundamentals
How does XERS's price correlate with its fundamentals
Growth
What is Xeris Pharmaceuticals's growth rate over time
Valuation
What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.36
XERS's EPS is up by 35% year-on-year and by 19% since the previous quarter
XERS's equity is down by 19% since the previous quarter
The company's revenue rose by 30% YoY and by 10% QoQ
XERS's price to sales (P/S) is 29% less than its 5-year quarterly average of 4.6 but 25% more than its last 4 quarters average of 2.6
Efficiency
How efficient is Xeris Pharmaceuticals business performance
XERS's ROS has soared by 66% year-on-year and by 42% since the previous quarter
The return on invested capital has surged by 59% year-on-year and by 35% since the previous quarter
The return on assets rose by 29% year-on-year and by 16% since the previous quarter
Dividends
What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XERS.
Financial health
How did Xeris Pharmaceuticals financials performed over time
The total assets is 10% less than the total liabilities
XERS's quick ratio is down by 36% year-on-year
XERS's current ratio is down by 27% year-on-year but it is up by 3% since the previous quarter
The debt to equity has soared by 74% YoY and by 17% from the previous quarter
XERS's equity is down by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.